Refractory Dyslipidemia After Liver Transplant: Case Study With Successive Histologic Investigations.
Hyperlipidemia is not unusual in liver transplant recipients, but refractory severe hyperlipidemia is unusual. We treated a 39-year-old man who had severe dyslipidemia after liver transplant. The levels of blood lipids, liver enzymes, and essential indicators of liver pathology were monitored. The first serum sample was collected from the liver recipient 56 days after transplant surgery because samples could not be obtained sooner after the transplant. The levels of liver enzymes and blood lipids were improved with symptomatic treatment but had recurrent fluctuations. Tacrolimus and cyclosporine, even at low doses, may have been the dominant factor affecting the blood lipid levels in the recipient.
From the Department of Transplantation, 302 Hospital, Beijing, China.
Zhou
Z
Xia
Xiao-bo
XB
Luo
Hai-bin
HB
Su
Yan-ling
YL
Sun
Zhang
Z
Min
Zhen-wen
ZW
Liu
D000328:Adult; D015415:Biomarkers / Q000097:blood; D001706:Biopsy; D016572:Cyclosporine / Q000009:adverse effects*; D057915:Drug Substitution; D004359:Drug Therapy, Combination; D006084:Graft Rejection / Q000209:etiology; D006801:Humans; D006949:Hyperlipidemias / Q000097:blood / Q000139:chemically induced* / Q000175:diagnosis / Q000628:therapy; D007166:Immunosuppressive Agents / Q000009:adverse effects*; D008055:Lipids / Q000097:blood*; D016031:Liver Transplantation / Q000009:adverse effects*; D008297:Male; D012307:Risk Factors; D016559:Tacrolimus / Q000009:adverse effects*; D013997:Time Factors; D016896:Treatment Outcome
D015415:Biomarkers; D007166:Immunosuppressive Agents; D008055:Lipids; D016572:Cyclosporine; D016559:Tacrolimus